Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to include babies under two months old with spinal muscular atrophy (SMA). The approval is based on interim efficacy and safety data from the RAINBOWFISH study in newborns, which showed that the majority of pre-symptomatic babies treated with Evrysdi achieved key milestones such as sitting and standing with half walking after 12 months of treatment.
FDA approves Roche’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)
May 31, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022